论文部分内容阅读
目的探讨乙型肝炎基因工程疫苗阻断HBV母婴传播的免疫保护效果和免疫策略。方法对HBsAg 和HBeAg 同时阳性母亲的169例新生儿接种国产重组酵母乙型肝炎疫苗 ,于免后3、9、12、24、36、48月采血进行血清免疫学追踪观察。结果22例婴儿1岁前HBsAg 阳性 ,19例 (11.24 % )成为慢性携带者 ,免后一年阻断保护率为85.94 %。抗 -HBs阳性率和抗 -HBs滴度均于9～12月龄时达一高峰 ,24和36月龄时有所下降 ,免后1～4年抗 -HBs阳性率分别为96.43 %、91.07 %、85.19 %和70.00 %。结论国产酵母重组乙型肝炎疫苗对HBV母婴传播具有良好免疫阻断效果。母亲HBsAg 和HBeAg 双阳性的幼儿在3～4岁时需加强免疫。
Objective To investigate the immunoprotective effect and immunization strategy of hepatitis B gene engineering vaccine to block the transmission of HBV from mother to infant. Methods 169 newborns with positive HBsAg and HBeAg positive mothers were inoculated with recombinant recombinant hepatitis B vaccine to observe the serum immunization after 3, 9, 12, 24, 36 and 48 months. Results Twenty-two infants were positive for HBsAg before the age of 1, and 19 (11.24%) became chronic carriers. The rate of one-year blocking protection was 85.94%. The positive rate of anti-HBs and the titer of anti-HBs reached a peak at 9 to 12 months of age and decreased at 24 and 36 months of age. The positive rates of anti-HBs in 1 to 4 years were 96.43% and 91.07 %, 85.19% and 70.00%. Conclusion Domestic yeast recombinant hepatitis B vaccine has good immunological blocking effect on HBV transmission. Mothers HBsAg and HBeAg double positive children in 3 to 4 years old need to strengthen the immune.